Description
Added on the 28/02/2023 16:32:12 - Copyright : Euronews EN
Wearing white laboratory coat and hair net, French President Emmanuel Macron tours the production site in Chartres, southwest of Paris, of Novo Nordisk . In a deal to be sealed officially with Macron today, Danish pharmaceutical giant Novo Nordisk will invest 2.1 billion euros ($2.3 billion) in this existing facility to expand capacity for a blockbuster anti-obesity drug. Novo Nordisk is the European Union's most valuable company with market capitalisation of around $460 billion, mostly thanks to growing use of its anti-diabetes drugs as weight-loss derivatives. IMAGES
On Thursday, Pfizer released a statement to deny claims that it was having issues producing its COVID-19 vaccine. The statement comes after officials in more than a dozen states complained that they were receiving fewer doses than promised. According to Business Insider, Trump officials claimed there were "manufacturing challenges." In its statement, Pfizer said it was "not having any production issues." It revealed it has millions of doses sitting in a warehouse, awaiting government orders on where to ship them to. Two anonymous Trump officials told the Associated Press the doses are in storage on purpose. The doses are being held back to ensure that people who had their first shot can get the second one.
FDA Commissioner Scott Gottlieb said that in November Pfizer offered the Trump Administration more COVID-19 vaccines. Gottlieb says the Trump administration rejected the offer. The NY Times reports that Pres. Trump rejected 100 million doses of Pfizer's recently approved COVID-19 vaccine over the summer. According to Business Insider the COVID-19 vaccine deployment campaign started Monday, December 14th.
An FDA advisory committee will meet next month to discuss an emergency use authorization. The emergency use authorization would be for Pfizer's COVID-19 vaccine. Earlier this week, Pfizer said clinical trials had shown its vaccine to be 95% effective. "While we cannot predict how long the FDA's review will take, the FDA will review the request as expeditiously as possible, while still doing so in a thorough and science-based manner," FDA Commissioner Stephen M. Hahn In October, the Emergency Care Research Institute warned against releasing a vaccine. They said six months of follow-up data on clinical trial participants is needed to move forward.
There are currently two COVID-19 vaccines promising results from their Phase 3 trials. Moderna announced that its vaccine was 94.5% effective. Pfizer/BioNTech announced that their vaccine was 95% effective. How long will it take for all Americans to be vaccinated? If the FDA approves the vaccine, Business Insider says first responders and vulnerable populations will receive vaccines through March. A new analysis from Morgan Stanley predict it will take four to nine months to vaccinate the general U.S. population.
The FDA approved remdesivir as a treatment for severe COVID-19 cases last month. This is after granting emergency authorization in May, reports Business Insider. But on Thursday, the WHO announced it will not recommend the drug's use for COVID-19 patients. "There is currently no evidence that it improves survival or the need for ventilation," the organization said. Remdesivir was the first coronavirus treatment to receive emergency authorization from the FDA. With Pfizer and Moderna's vaccines on the horizon, there is less of a need for weaker treatments.
|
Support : Technical 
- Content 
- Editors 
